U.S. Orthopedic Biomaterials - Industry Report

The U.S. orthopedic biomaterials market size accounted for USD 5,930 million in 2024 and is expected to exceed around USD 12,570 million by 2034, growing at a CAGR of 7.8% from 2025 to 2034.

U.S. Orthopedic Biomaterials Market Report Highlights

• By material, the ceramics & bioactive glass segment dominated the market in 2024.
• By material, the polymers segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By application, the orthopedic implant segment dominated the orthopedic biomaterials market in 2024.
• By application, the joint replacement segment is predicted to witness significant growth in the market over the forecast period.
• By end user, the hospitals segment registered its dominance over the market in 2024.
• By end user, the orthopedic clinics segment is anticipated to grow with the highest CAGR in the market during the studied years.

The U.S. orthopedic biomaterials market refers to the production, distribution, and application of orthopedic biomaterial, which is mainly designed to restore the normal function and properties of impaired tissue. Biomaterial is derived from or produced by biological organisms like fungi, bacteria, animals, plants, and other life forms. It is also known as biologically derived materials. This material is used for biological purposes such as biomedical applications like treating an injury or growing biological cells. Orthopedics is a branch of medicine dealing with the correction or prevention of deformities, disorders, or injuries of the skeleton and structures closely associated with it. Magnesium (Mg) alloys are among the promising materials suitable for biodegradable orthopedic applications. The use of hydroxyapatite (HA) can help in tailoring the bioactivity and biodegradation behavior of such alloys. Biomaterials are used for grafts, dental implants, hearing loss implants, tendons, ligaments, artificial joints, and devices that stimulate nerves.

Regulatory advancements and approvals are driving the growth of the U.S. orthopedic biomaterials market. Technological advancements in regulatory affairs provide opportunities for improving the approval process, enabling regulatory affairs professionals to manage submissions, communications, and monitoring more effectively by speeding up the journey from development to market. The main objective of regulatory affairs is to provide the basis for the assurance of high-quality food products, which can increase consumers’ interest in ensuring safety, efficacy, and quality. Regulatory approvals is a generic term that covers licenses, permissions, or authorization granted by a Government, state agency, or regulatory authorities to an individual or business entity permitting the manufacturing of a service, development of a project, or other similar undertakings. Regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are continually enhancing guidelines and approval processes for new orthopedic biomaterials.

The integration of stem cell technology and regenerative medicines is driving the growth of the U.S. orthopedic biomaterials market. The integration of stem cell technology and regenerative medicine advanced therapies aims to promote the body’s natural healing process by using stem cells to regenerate damaged tissues and bones. When biomaterials are combined with hydrogels and scaffolds, regenerative medicine can improve healing outcomes and accelerate tissue regeneration. Autologous bone marrow or autologous mesenchymal stem cells can be implanted in many patients to improve fracture/osteotomy healing, osteonecrosis, and bone cysts, treat pseudarthrosis, fill bone defects, or improve spinal fusion. These cells can be easily isolated, processed, and made available for clinical use. From healing of bone defects caused by trauma, tumor, or infection to cartilage defects and nerve, tendon, and ligament healing, stem cell use has the potential to transform orthopedic practice.

Rising demand for minimally invasive procedures contributes to the growth of the U.S. orthopedic biomaterials market. A minimally invasive procedure offers many benefits. These include reduced trauma to the body, decreased blood loss during surgery, and a lower risk of surgical complications. Innovations in surgical technology and techniques are enabling surgeons to complete more operations using minimally invasive procedures. By accessing your organs through smaller portals, surgeons can minimize surgical trauma by reducing pain, recovery time, and complications. Minimally invasive orthopedic procedures involve making small incisions and using innovative medical technology to access and treat the affected area. Arthroscopic surgeons use small cameras, which are used in the incisions, enabling them to see inside the joint on a monitor.

Personalized orthopedic solutions also help the growth of the U.S. orthopedic biomaterials market. Personalized non-surgical treatment plans include lifestyle modifications, exercise programs, and physical therapy routines. This personalized approach minimizes complications, improves patient comfort, and accelerates recovery, ultimately leading to enhanced outcomes. Personalized surgery is transforming orthopedic care, leading to more accurate and successful procedures. Wearable sensors can provide feedback to patients, reminding them of activity restrictions, medication schedules, or rehabilitation exercises so that they follow post-operative care instructions.